Table 1.
Overview of HAT1 expression and related outcomes in different cancer types.
| Cancer Type | HAT1 Expression | Outcomes | References |
|---|---|---|---|
| Pancreatic cancer (PC) | High | Resistance to chemotherapy and radiotherapy Poor prognosis |
[31] |
| Colorectal cancer (CRC) | High Low |
Not reported | [43,54] |
| Hepatocellular carcinoma (HCC) | High | Resistance to chemotherapy | [44] |
| Esophageal squamous cancer (ESC) | High | Poor tumor differentiation | [45] |
| Uterine leiomyosarcoma (LMS) | High | Poor clinical prognosis Resistant to chemotherapy and radiotherapy |
[46] |
| Nasopharyngeal carcinoma (NPC) | High | Not reported | [47] |
| Cervical cancer (CC) | High | Poor prognosis | [49] |
| Lip squamous cell carcinoma (LSCC) | High | Represents 2.1% of all cancers | [50] |
| Actinic cheilitis (AC) | High | Represents 2.1% of all cancers | [50] |
| Breast cancer (BC) | High | Poor prognosis | [51] |
| Diffuse large B-cell lymphoma (DLBCL) | High | Tumor invasion and metastasis Poor prognosis |
[52] |
| Peripheral T-cell lymphoma (PTCL) | High | Tumor invasion and metastasis Poor prognosis |
[52] |
| Lung cancer cell (LCC) | Low | Five-year survival rate is less than 20% | [53] |
| Melanoma | Low | Resistance to chemotherapy | [55] |